miR-295-3P antagomir

miR-295-3P antagomir has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Feb 6, 2026: “Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on miR-295-3P antagomir

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: Beijing Municipal Natural Science Foundation and 4 more
  • Animals1

What did studies of miR-295-3P antagomir find?

1

Studies of miR-295-3P antagomir measured one outcome, heart failure with preserved ejection fraction.

Heart failure with preserved ejection fraction

downin mice1

1 study
  1. miR-295-3P antagomir decreases heart failure with preserved ejection fraction in HFpEF mice.

    “MiR-295-3p antagomir treatment mitigated HFpEF phenotypes.”

    Animalsin HFpEF miceheartmales

    Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction

    Cardiovascular research

More on Heart failure with preserved ejection fraction

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months